IQVIA Holdings Inc. $IQV Stake Lowered by Vision Capital Management Inc.

Vision Capital Management Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,641 shares of the medical research company’s stock after selling 3,752 shares during the period. IQVIA accounts for about 0.7% of Vision Capital Management Inc.’s investment portfolio, making the stock its 29th biggest holding. Vision Capital Management Inc.’s holdings in IQVIA were worth $6,356,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Apella Capital LLC boosted its stake in IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after acquiring an additional 55 shares during the last quarter. Breakwater Capital Group lifted its stake in shares of IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the period. Fortitude Family Office LLC lifted its stake in shares of IQVIA by 17.2% in the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 65 shares during the period. First Growth Capital LLC boosted its position in shares of IQVIA by 3.2% in the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after purchasing an additional 68 shares during the last quarter. Finally, Chicago Partners Investment Group LLC boosted its position in shares of IQVIA by 1.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock worth $812,000 after purchasing an additional 70 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 0.4%

IQV opened at $265.72 on Tuesday. The firm’s fifty day moving average is $261.23 and its two-hundred day moving average is $213.85. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market cap of $43.74 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 2.32 and a beta of 1.17. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period last year, the firm posted $2.81 earnings per share. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock worth $3,796,021 in the last three months. 1.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IQV. William Blair raised IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. TD Cowen increased their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Truist Financial restated a “buy” rating and set a $329.00 target price (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. Finally, Morgan Stanley boosted their target price on IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.00.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.